NOVELTY – Liposomal pharmaceutical composition comprises more than 98% of isotretinoin or its derivative, which is encapsulated in liposome. USE – Liposomal pharmaceutical composition used for treating skin disorders e.g. acne, psoriasis, skin aging (claimed) and skin cancer. ADVANTAGE – The liposomal pharmaceutical composition has reduced side effects e.g. skin irritation with increased therapeutic efficacy, and decreases chemical degradation of isotretinoin and increases 98% of drug encapsulation efficiency of the composition. The preparing method for the composition is cost-effective. DETAILED DESCRIPTION – An INDEPENDENT CLAIM is also included for a method for preparing pharmaceutical composition, which involves: (A) dissolving lipophilic constituents and isotretinoin in organic solvent; (B) forming a mixture of dry ingredients after evaporating solvent from the dissolved mixture; (C) adding an aqueous phase to the mixture for hydrating dry mixture; (D) agitating the mixture; and (E) incorporating the mixture with a carrier to obtain desired product.
A96 (Medical, dental, veterinary, cosmetic.); B07 (General – tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.); B01 (Steroids – including systems containing carbocyclic and/or heterocyclic rings fused onto the basic steroidal ring structure.); B05 (Other organics – aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 – B05.)